On Friday, Gilead Sciences highlighted clinical data showing one of its candidates offered benefits across multiple liver diseases. Analysts, however, remain unconvinced the drug can stack up to rival therapies that work in a similar way.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,